SCHEMBL20001148

SCHEMBL20001148

C[C@]1(CC(=O)Nc2nccs2)NCCc2cc(OCc3ncccn3)c(Oc3ccc(-c4ccc(C(=O)O)cc4)c(F)c3)cc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PCSK9 Q8NBP7 4/20 0.42
MAP1LC3B Q9GZQ8 4/20 0.42
SCN9A Q15858 4/20 0.35
SYK P43405 1/20 0.33
FEN1 P39748 1/20 0.33
BRD4 O60885 1/20 0.32
LMNA P02545 1/20 0.32
L3MBTL1 Q9Y468 2/20 0.32
NPC1 O15118 2/20 0.32
TP53 P04637 2/20 0.32
HPGD P15428 2/20 0.32
RAB9A P51151 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
ALOX15 P16050 1/20 0.32
ALDH1A1 P00352 3/20 0.32
KMT2A Q03164 2/20 0.32
TSHR P16473 1/20 0.32
MEN1 O00255 1/20 0.32
MAPT P10636 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22687384 1.00 PCSK9 (0.42) PCSK9MAP1LC3BSCN9ASYKFEN1
SCHEMBL22687412 0.93 PCSK9 (0.43) PCSK9MAP1LC3BSCN9ASYKCSNK2A2
SCHEMBL20001147 0.93 PCSK9 (0.43) PCSK9MAP1LC3BSCN9ASYKCSNK2A2
SCHEMBL30228831 0.93 PCSK9 (0.43) PCSK9MAP1LC3BSCN9ASYKCSNK2A2
SCHEMBL22687424 0.92 PCSK9 (0.47) PCSK9MAP1LC3BSCN9ALMNAL3MBTL1
SCHEMBL20001132 0.92 PCSK9 (0.47) PCSK9MAP1LC3BSCN9ALMNAL3MBTL1
SCHEMBL20001067 0.91 PCSK9 (0.47) PCSK9MAP1LC3BBRD4LMNAL3MBTL1
SCHEMBL22687386 0.91 PCSK9 (0.47) PCSK9MAP1LC3BBRD4LMNAL3MBTL1
SCHEMBL20001130 0.91 SCN9A (0.35) PCSK9MAP1LC3BSCN9ASYKFEN1
SCHEMBL19995729 0.90 PCSK9 (0.43) PCSK9MAP1LC3BSCN9AFEN1BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3515891-B1 SUBSTITUTED 1-METHYL-1,2,3,4-TETRAHYDROISOQUINOLINE MOLECULES AS PCSK9 ALLOSTERIC BINDERS MERCK SHARP & DOHME LLC (US) 2023-03-08 EP disclosed
US-11008313-B2 Substituted 1-methyl-1,2,3,4-tetrahydroisoquinoline molecules as PCSK9 allosteric binders MERCK SHARP & DOHME CORP. (US) 2021-05-18 US disclosed
US-11008313-B2 Substituted 1-methyl-1,2,3,4-tetrahydroisoquinoline molecules as PCSK9 allosteric binders MERCK SHARP & DOHME CORP. (US) 2021-05-18 US disclosed
US-20200369657-A1 SUBSTITUTED 1-METHYL-1,2,3,4-TETRAHYDROISOQUINOLINE MOLECULES AS PCSK9 ALLOSTERIC BINDERS MERCK SHARP & DOHME CORP. (US) 2020-11-26 US disclosed
US-20200369657-A1 SUBSTITUTED 1-METHYL-1,2,3,4-TETRAHYDROISOQUINOLINE MOLECULES AS PCSK9 ALLOSTERIC BINDERS MERCK SHARP & DOHME CORP. (US) 2020-11-26 US disclosed
WO-2018057409-A1 SUBSTITUTED 1-METHYL-1,2,3,4-TETRAHYDROISOQUINOLINE MOLECULES AS PCSK9 ALLOSTERIC BINDERS MERCK SHARP & DOHME CORP. (US) 2018-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200369657-A1 SUBSTITUTED 1-METHYL-1,2,3,4-TETRAHYDROISOQUINOLINE MOLECULES AS PCSK9 ALLOSTERIC BINDERS PCSK9, PCSK7, LDLR PCSK9 1/4885MAP1LC3B 2259/4885SCN9A 2941/4885
US-11008313-B2 Substituted 1-methyl-1,2,3,4-tetrahydroisoquinoline molecules as PCSK9 allosteric binders PCSK9, PCSK7, LDLR PCSK9 1/4885MAP1LC3B 2190/4885SCN9A 2873/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.